- Home
- ARCT vs GEVO Comparison
ARCT vs GEVO Comparison
Compare ARCT & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- GEVO
- Stock Information
- Founded
- ARCT 2013
- GEVO 2005
- Country
- ARCT United States
- GEVO United States
- Employees
- ARCT N/A
- GEVO N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- ARCT Health Care
- GEVO Industrials
- Exchange
- ARCT Nasdaq
- GEVO Nasdaq
- Market Cap
- ARCT 298.3M
- GEVO 246.8M
- IPO Year
- ARCT N/A
- GEVO 2011
- Fundamental
- Price
- ARCT $12.10
- GEVO $1.13
- Analyst Decision
- ARCT Strong Buy
- GEVO Buy
- Analyst Count
- ARCT 8
- GEVO 2
- Target Price
- ARCT $52.33
- GEVO $7.58
- AVG Volume (30 Days)
- ARCT 484.3K
- GEVO 3.4M
- Earning Date
- ARCT 08-04-2025
- GEVO 05-13-2025
- Dividend Yield
- ARCT N/A
- GEVO N/A
- EPS Growth
- ARCT N/A
- GEVO N/A
- EPS
- ARCT N/A
- GEVO N/A
- Revenue
- ARCT $143,680,000.00
- GEVO $42,034,000.00
- Revenue This Year
- ARCT N/A
- GEVO $631.78
- Revenue Next Year
- ARCT $39.32
- GEVO $80.71
- P/E Ratio
- ARCT N/A
- GEVO N/A
- Revenue Growth
- ARCT 15.38
- GEVO 145.38
- 52 Week Low
- ARCT $8.04
- GEVO $0.48
- 52 Week High
- ARCT $45.00
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- ARCT 48.75
- GEVO 47.89
- Support Level
- ARCT $11.51
- GEVO $1.00
- Resistance Level
- ARCT $13.27
- GEVO $1.22
- Average True Range (ATR)
- ARCT 0.82
- GEVO 0.08
- MACD
- ARCT 0.01
- GEVO 0.00
- Stochastic Oscillator
- ARCT 26.15
- GEVO 21.87
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.